

UC Davis

Nephrology

Title

ASSOCIATION OF SELF-REPORTED AND OBJECTIVE MEASURES OF PHYSICAL ACTIVITY WITH LEG MUSCLE MITOCHONDRIAL OXIDATIVE CAPACITY IN CKD

Permalink

<https://escholarship.org/uc/item/8k5198tp>

Authors

Bae, Se Ri

Kim, Tae Youn

Gamboa, Jorge

et al.

Publication Date

2021

Data Availability

The data associated with this publication are not available for this reason: N/A

ASSOCIATION OF SELF-REPORTED AND
OBJECTIVE MEASURES OF PHYSICAL
ACTIVITY WITH LEG MUSCLE
MITOCHONDRIAL OXIDATIVE CAPACITY
IN CKD

Se Ri Bae¹ Tae Youn Kim² Jorge Gamboa³ Chenoa Vargas⁴ Sophia Liu⁵ Kushang Patel⁶ Ian de Boer⁷ Bryan Kestenbaum^{7,8} Baback Roshanravan⁴

¹University of California, Davis, School of Medicine

²University of California, Davis, School of Nursing

³Vanderbilt University, Department of Medicine

⁴University of California, Davis, Department of Internal Medicine, Division of Nephrology

⁵University of Washington

⁶University of Washington, Department of Anesthesiology and Pain Medicine

⁷University of Washington, Department of Medicine, Division of Nephrology

⁸University of Washington, Department of Epidemiology

UC DAVIS
HEALTH



 **KIDNEY
RESEARCH
INSTITUTE**

BACKGROUND

- Chronic kidney disease (CKD) is associated with skeletal muscle dysfunction leading to decreased physical functioning.
- Reduced kidney function leads to impaired muscle mitochondrial oxidative capacity underlying poor physical performance.
- The link between muscle mitochondrial oxidative capacity and patient-reported and objective measures of physical activity (PA) remains unclear.

OBJECTIVE

- To determine the association between in-vivo leg muscle mitochondrial capacity and self-reported PA and objective PA.

METHODS

- We performed a cross-sectional study of participants from the Chronic Kidney Mitochondrial Energetics and Dysfunction (CKD-MEND) study.
- Muscle mitochondrial oxidative capacity (ATPmax) in the tibialis anterior muscle was measured using in vivo ³¹P Phosphorus Magnetic Resonance Spectroscopy.
- We assessed patient-reported PA with the Human Activity Profile (HAP) questionnaire and objective PA with log-transformed accelerometry counts from an Actigraph accelerometer worn over a 14-day period.
- Multivariable linear regression was used to test associations between CKD status with ATPmax in nested models separately adjusting for HAP scores or accelerometry values.

Table 1. Participant characteristics

	CKD (N=40)	Control (N=19)
Age (years), mean (SD)	62 (14)	60 (8)
Female, No (%)	22 (55)	6 (32)
Black, No (%)	5 (13)	2 (11)
Diabetes, No (%)	12 (30)	6 (32)
BMI (kg/m ²), mean (SD)	28.7 (6)	27.2 (5)
Systolic BP (mmHg), mean (SD)	127 (18)	129 (12)
eGFR _{cr-cysc} (ml/min per 1.73m ²) (SD)	38 (19)	98 (14)
Hemoglobin (gm/dL), mean (SD)	13 (2)	14.3 (2)
Bicarbonate (mmol/L) , mean (SD)	21.9 (3)	22.8 (1.7)

RESULTS

Figure 1. Association of ATPmax with objective PA






Figure 2. Association of ATPmax with self-reported PA



ATPmax was more strongly associated with accelerometry counts (objective PA) than HAP scores (self-reported PA).

RESULTS

Figure 3. Linear regression models of the association of CKD with ATPmax



- Accelerometry counts explained 43% of the difference in leg muscle ATPmax between CKD and controls (-0.106 mM/s, $p=0.02$) while HAP scores accounted for 15% of the ATPmax differences (-0.158 mM/s, $p < 0.01$) after adjusting for sex, age, BMI, and diabetes.
- Diabetes and CKD were independently associated with lower ATPmax (-0.118 mM/s, $p < 0.01$ and -0.186 mM/s, $p < 0.01$, respectively).

CONCLUSIONS

- Objective PA measure of accelerometry counts is more strongly associated with ATPmax and explains more of the differences in ATPmax between CKD and controls than self-reported PA.
- Objective physical activity better captures the influence of habitual physical activity on muscle mitochondrial capacity.
- Further studies are needed to demonstrate if increased structured PA can improve mitochondrial oxidative capacity.

ACKNOWLEDGEMENTS

Northwest Kidney Centers

NIDDK funding: K23DK099442, R01DK101509, R03DK114502

Dialysis Clinics Inc.